Published in Bioconjug Chem on December 11, 2007
Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem (2009) 1.88
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev (2008) 1.55
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging (2009) 1.28
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics (2011) 1.25
Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem (2008) 1.18
2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem (2009) 1.01
Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Mol Imaging (2010) 1.01
99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging (2009) 0.97
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clin Cancer Res (2012) 0.96
Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics (2011) 0.95
Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconjug Chem (2010) 0.92
Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency. Bioconjug Chem (2011) 0.88
Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins. Bioconjug Chem (2015) 0.86
Triazine-based tool box for developing peptidic PET imaging probes: syntheses, microfluidic radiolabeling, and structure-activity evaluation. Bioconjug Chem (2014) 0.82
Evaluation of 99mTc-labeled cyclic RGD peptide with a PEG4 linker for thrombosis imaging: comparison with DMP444. Bioconjug Chem (2011) 0.80
Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo. Cancer Biother Radiopharm (2014) 0.75
Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor. Cell Biochem Biophys (2014) 0.75
Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep (2016) 0.75
Integrin signaling and cell growth control. Curr Opin Cell Biol (1998) 3.32
Fundamental concepts of the angiogenic process. Curr Mol Med (2003) 3.16
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Integrins: roles in cancer development and as treatment targets. Br J Cancer (2004) 2.76
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm (2006) 2.16
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med (2005) 1.94
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol (2004) 1.72
Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem (2006) 1.70
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging (2004) 1.60
Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des (2004) 1.59
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res (2002) 1.47
Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem (2007) 1.39
Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm (2003) 1.29
Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med (1994) 1.29
Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem (2001) 1.28
Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol (2007) 1.18
Integrin-mediated signal transduction. Cell Mol Life Sci (1998) 1.17
90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent. Bioconjug Chem (2004) 1.13
99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Bioconjug Chem (2006) 1.07
99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem (2001) 1.07
Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem (2005) 1.05
Tumor angiogenesis targeting using imaging agents. Q J Nucl Med (2001) 1.03
Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med (2005) 1.02
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med (1999) 1.01
Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. Bioconjug Chem (2006) 1.00
Radiotracer-based strategies to image angiogenesis. Q J Nucl Med (2003) 0.99
Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm (2004) 0.99
Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. Bioconjug Chem (2007) 0.97
Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J Med Chem (1998) 0.95
Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjug Chem (2006) 0.95
Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. Nucl Med Biol (2007) 0.94
(90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem (2001) 0.92
Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun (1998) 0.91
Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. Eur J Nucl Med Mol Imaging (2002) 0.89
Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). Q J Nucl Med (2003) 0.86
Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates. Bioconjug Chem (2001) 0.82
Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med (1994) 0.82
Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents. Bioconjug Chem (2007) 0.81
Isomerism and solution dynamics of (90)Y-labeled DTPA--biomolecule conjugates. Bioconjug Chem (2001) 0.79
Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. Nucl Med Biol (1998) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell (2009) 6.44
MicroRNA-mediated control of oligodendrocyte differentiation. Neuron (2010) 3.24
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell (2010) 2.83
SLIT2-mediated ROBO2 signaling restricts kidney induction to a single site. Dev Cell (2004) 2.74
Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell (2003) 2.54
Deletion of PIK3C3/Vps34 in sensory neurons causes rapid neurodegeneration by disrupting the endosomal but not the autophagic pathway. Proc Natl Acad Sci U S A (2010) 2.53
In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther (2008) 2.34
The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. Nat Neurosci (2012) 2.28
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol (2010) 2.20
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials (2009) 2.13
Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. Proc Natl Acad Sci U S A (2008) 2.08
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing. Cell Cycle (2010) 2.06
Unc-51-like kinase 1/2-mediated endocytic processes regulate filopodia extension and branching of sensory axons. Proc Natl Acad Sci U S A (2007) 1.95
MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem (2010) 1.94
Toward reliable characterization of functional homogeneity in the human brain: preprocessing, scan duration, imaging resolution and computational space. Neuroimage (2012) 1.92
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun (2012) 1.72
GAP production of TCM herbs in China. Planta Med (2010) 1.70
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Analyzing somatosensory axon projections with the sensory neuron-specific Advillin gene. J Neurosci (2007) 1.67
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A (2010) 1.66
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
DNA methylation presents distinct binding sites for human transcription factors. Elife (2013) 1.63
Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (2012) 1.61
Shape- and size-dependent refractive index sensitivity of gold nanoparticles. Langmuir (2008) 1.60
Mechanism for myocardial localization and rapid liver clearance of Tc-99m-N-MPO: a new perfusion radiotracer for heart imaging. J Nucl Cardiol (2009) 1.56
A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med (2014) 1.53
Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J Biol Chem (2010) 1.52
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res (2004) 1.52
Kinetic characterization of a novel cationic (99m)Tc(I)-tricarbonyl complex, (99m)Tc-15C5-PNP, for myocardial perfusion imaging. J Nucl Cardiol (2010) 1.50
N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev (2009) 1.45
Candidate pathway-based genome-wide association studies identify novel associations of genomic variants in the complement system associated with coronary artery disease. Circ Cardiovasc Genet (2014) 1.45
A 128-channel 6 mW wireless neural recording IC with spike feature extraction and UWB transmitter. IEEE Trans Neural Syst Rehabil Eng (2009) 1.45
SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics (2010) 1.45
Functional genomics analysis of Singapore grouper iridovirus: complete sequence determination and proteomic analysis. J Virol (2004) 1.44
Spatiotemporal patterns of the fish assemblages downstream of the Gezhouba Dam on the Yangtze River. Sci China Life Sci (2012) 1.41
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Do gluons carry half of the nucleon momentum? Phys Rev Lett (2009) 1.39
Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem (2007) 1.39
Spin and orbital angular momentum in gauge theories: nucleon spin structure and multipole radiation revisited. Phys Rev Lett (2008) 1.39
Extraordinary photoluminescence and strong temperature/angle-dependent Raman responses in few-layer phosphorene. ACS Nano (2014) 1.38
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
Tailoring longitudinal surface plasmon wavelengths, scattering and absorption cross sections of gold nanorods. ACS Nano (2008) 1.35
Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging (2009) 1.35
MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett (2011) 1.34
Retrograde BMP signaling regulates trigeminal sensory neuron identities and the formation of precise face maps. Neuron (2007) 1.34
Human health risk assessment of heavy metals in soil-vegetable system: a multi-medium analysis. Sci Total Environ (2013) 1.33
Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur Urol (2011) 1.31
Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med (2006) 1.31
Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm (2003) 1.29
New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv (2009) 1.29
Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med (2009) 1.29
Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res (2009) 1.28
(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging (2009) 1.28
Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis. PLoS One (2013) 1.28
New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr Opin Microbiol (2011) 1.26
Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem (2009) 1.26
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
Assessment of association of rs2200733 on chromosome 4q25 with atrial fibrillation and ischemic stroke in a Chinese Han population. Hum Genet (2009) 1.25
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics (2011) 1.25
Rapid large-scale preparation of ZnO nanowires for photocatalytic application. Nanoscale Res Lett (2011) 1.24
New modules are added to vibrissal premotor circuitry with the emergence of exploratory whisking. Neuron (2013) 1.24
PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res (2003) 1.23
99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med (2012) 1.23
Crystal structure of type I ryanodine receptor amino-terminal beta-trefoil domain reveals a disease-associated mutation "hot spot" loop. Proc Natl Acad Sci U S A (2009) 1.22
Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat (2008) 1.22
The prognostic value of the Tpeak-Tend interval in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Electrocardiol (2009) 1.21
Strong polarization dependence of plasmon-enhanced fluorescence on single gold nanorods. Nano Lett (2009) 1.21
Proper formation of whisker barrelettes requires periphery-derived Smad4-dependent TGF-beta signaling. Proc Natl Acad Sci U S A (2011) 1.20
(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem (2009) 1.19
Activity-induced remodeling of olfactory bulb microcircuits revealed by monosynaptic tracing. PLoS One (2011) 1.19
Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol (2007) 1.18
Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene (2005) 1.18
A DIFFUSE-INTERFACE APPROACH FOR MODELING TRANSPORT, DIFFUSION AND ADSORPTION/DESORPTION OF MATERIAL QUANTITIES ON A DEFORMABLE INTERFACE. Commun Math Sci (2009) 1.18
Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem (2008) 1.18
Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res (2008) 1.17
Intrinsically copper-64-labeled organic nanoparticles as radiotracers. Angew Chem Int Ed Engl (2012) 1.16
Differential earth mover's distance with its applications to visual tracking. IEEE Trans Pattern Anal Mach Intell (2010) 1.16
The mammalian class 3 PI3K (PIK3C3) is required for early embryogenesis and cell proliferation. PLoS One (2011) 1.15
Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm (2013) 1.15
MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer (2014) 1.14
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (2008) 1.14